MicroRNA 4770 (hsa-miR-4770)

MicroRNA 4770 (hsa-miR-4770) is a human microRNA identified as a downregulated molecule in gallbladder carcinoma, suggesting its potential role as a diagnostic biomarker and possibly a therapeutic target for this malignancy[1]. MicroRNAs function by binding to target messenger RNAs (mRNAs) to inhibit their translation or promote their degradation, thereby regulating gene expression post-transcriptionally[2][4]. The regulatory network of hsa-miR-4770 in gallbladder carcinoma involves a complex ceRNA (competing endogenous RNA) system, with targets including mRNAs associated with cell cycle regulation, apoptosis, adhesion, extracellular matrix interactions, and p53 pathway signaling[1]. The ceRNA network analysis identified several oncogenes and tumor suppressors (e.g., BRCA1, CHEK2, RB1, CASP8, PTGS2, CD44, KRT19, CDK1, PVT1, MXRA5) as interconnected with hsa-miR-4770, further supporting its role in cancer biology[1]. There are no approved drugs directly modulating hsa-miR-4770, but general approaches may include development of miRNA mimics or antagomirs to alter its expression or function.

Other names

MIR4770hsa-miR-4770microRNA 4770

Modulation would occur via RNA interference, mimics, or inhibitors; no specific drugs with defined mechanism for targeting hsa-miR-4770 are currently known.